For how we live.
A prespecified analysis of 131,276 older adults found RSVpreF cut RSV hospitalisations overall. In the immunosuppressed, baseline risk was nine times higher — but the subgroup was too small to prove it helped them.
Two pragmatic randomised trials and a Medicare nursing home cohort landed in the same week. Together they show real protection against hospitalisation and a durability question nobody has answered.
A Buenos Aires surveillance cohort estimates 80.8% effectiveness against RSV hospitalisation in infants under three months — close to what the licensing trial found, in a real programme.